

DAFTAR PUSTAKA

1. Abdel-Daim, M. M. *et al.* (2020) 'Protective effects of thymoquinone against acrylamide-induced liver, kidney and brain oxidative damage in rats', *Environmental Science and Pollution Research*, 27(30), pp. 37709–37717. doi: 10.1007/s11356-020-09516-3.
2. Adam, G. O. *et al.* (2016) 'Hepatoprotective effects of Nigella sativa seed extract against acetaminophen-induced oxidative stress', *Asian Pacific Journal of Tropical Medicine*, 9(3), pp. 221–227. doi: 10.1016/j.apjtm.2016.01.039.
3. Ahmad, A. *et al.* (2013) 'review on therapeutic potential of Nigella sativa : A miracle herb', *Asian Pac J Trop Biomed*, 3(5), pp. 337–352. doi: 10.1016/S2221-1691(13)60075-1.
4. Albassam, A. A. *et al.* (2018) 'Inhibition of cytochrome P450 enzymes by thymoquinone in human liver microsomes', *Saudi Pharmaceutical Journal*, 26(5), pp. 673–677. doi: 10.1016/j.jsps.2018.02.024.
5. Ali, B. *et al.* (2012) 'Bioavailability enhancement studies of amoxicillin with Nigella', *The Indian journal of medical research*, 135(4), pp. 555–559.
6. Ali, B. H. and Blunden, G. (2003) 'Pharmacological and Toxicological Properties of Nigella sativa', *PHYTOTHERAPY RESEARCH*, 305(November 2002), pp. 299–305. doi: 10.1002/ptr.1309.
7. Alkharfy, K. M. *et al.* (2018) 'Thymoquinone reduces mortality and suppresses early acute inflammatory markers of sepsis in a mouse model', *Biomedicine and Pharmacotherapy*, 98(January), pp. 801–805. doi: 10.1016/j.biopha.2018.01.028.
8. Altamura, A. C. and Buoli, M. (2014) 'Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia', *Psychiatry and Clinical Neurosciences*, pp. 21–36. doi: 10.1111/pcn.12089.
9. APA (2013) *Diagnostic and Statistical Manual of Mental Disorders Fifth Edition*. American Psychiatric Association.
10. Bamosa, A. O. *et al.* (2010) 'Effect of Nigella Sativa seeds on the glycemic control of patients with type 2 diabetes mellitus', *Indian Journal of Physiology and Pharmacology*, 54(4), pp. 344–354.
11. Bargi, R. *et al.* (2017) 'The effects of thymoquinone on hippocampal cytokine level, brain oxidative stress status and memory deficits induced by lipopolysaccharide in rats', *Cytokine*, 96(April), pp. 173–184. doi: 10.1016/j.cyto.2017.04.015.
12. Bitanihirwe, B. K. Y. and Woo, T. W. (2011) 'Neuroscience and Biobehavioral Reviews Oxidative stress in schizophrenia: An integrated approach', *Neuroscience and Biobehavioral Reviews*, 35(3), pp. 878–893. doi: 10.1016/j.neubiorev.2010.10.008.
13. Chan, V. (2017) 'Schizophrenia and Psychosis Transitional Age Youth Schizophrenia Psychotic disorders Therapeutics Education Adolescence', *Child and Adolescent Psychiatry Clinics of NA*, 26(2), pp. 341–366. doi: 10.1016/j.chc.2016.12.014.
14. Cho, M. *et al.* (2019) 'Adjunctive use of anti-inflammatory drugs for schizophrenia : A meta-analytic investigation of randomized controlled trials', *Australian & New Zealand Journal of Psychiatry*, 53(8), pp. 742–759. doi: 10.1177/0004867419835028.
15. Cobourne-duval, M. K. *et al.* (2018) 'Thymoquinone increases the expression of neuroprotective proteins while decreasing the expression of pro-inflammatory cytokines and the gene expression NF κ B pathway signaling targets in LPS / IFN γ -activated BV-2 microglia cells', *Journal of Neuroimmunology*, 320(April), pp. 87–97. doi: 10.1016/j.jneuroim.2018.04.018.
16. Davis, J. *et al.* (2014) 'Neuroprogression in schizophrenia : Pathways underpinning clinical staging and therapeutic corollaries', *Aust N Z J Psychiatry*, (May). doi: 10.1177/0004867414533012.
17. Dollah, M. A. *et al.* (2013) 'Toxicity effect of Nigella sativa on the liver function of rats', *Advanced Pharmaceutical Bulletin*, 3(1), pp. 97–102. doi: 10.5681/apb.2013.016.
18. Feng, Z. *et al.* (2020) 'Effects of risperidone on blood levels of interleukin-6 in schizophrenia: A meta-analysis', *Medicine*, 99(15), p. e19694. doi: 10.1097/MD.00000000000019694.
19. Francesconi, L. P. *et al.* (2018) 'Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the', pp. 84–88. doi: 10.1097/YIC.0000000000000241.
20. Frommberger, U. H. *et al.* (1997) 'Interleukin-6-(IL-6) plasma levels in depression and

- schizophrenia: Comparison between the acute state and after remission', *European Archives of Psychiatry and Clinical Neuroscience*, 247(4), pp. 228–233. doi: 10.1007/BF02900219.
21. Hamed, M. A., El-Rigal, N. S. and Ali, S. A. (2013) 'Effects of black seed oil on resolution of hepato-renal toxicity induced by bromobenzene in rats', *European Review for Medical and Pharmacological Sciences*, 17(5), pp. 569–581.
 22. Hobbenaghi, R. *et al.* (2014) 'Journal of the Neurological Sciences Neuroprotective effects of Nigella sativa extract on cell death in hippocampal neurons following experimental global cerebral ischemia-reperfusion injury in rats', *Journal of the Neurological Sciences*, 337(1–2), pp. 74–79. doi: 10.1016/j.jns.2013.11.019.
 23. Hosseini, M., Zakeri, S. and Khoshdast, S. (2012) 'The effects of Nigella sativa hydro-alcoholic extract and thymoquinone on lipopolysaccharide - induced depression like behavior in rats', *Journal of Pharmacy and Bioallied Sciences*, 4(3). doi: 10.4103/0975-7406.99052.
 24. Kanter, M. L. *et al.* (2006) 'Neuroprotective effects of Nigella sativa on experimental spinal cord injury in rats', *Human & Experimental Toxicology*, 25(3), pp. 127–133. doi: doi.org/10.1191/0960327106ht608oa.
 25. Khandaker, G. M. *et al.* (2015) 'Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment', *The Lancet Psychiatry*, 2(3), pp. 258–270. doi: 10.1016/S2215-0366(14)00122-9.
 26. Kirkpatrick, B. and Miller, B. J. (2013) 'Inflammation and Schizophrenia', *Schizophrenia Bulletin*, 39(6), pp. 1174–1179. doi: 10.1093/schbul/sbt141.
 27. Kooti, W. *et al.* (2016) 'Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa)', *Chinese Journal of Natural Medicines*, 14(10), pp. 732–745. doi: 10.1016/S1875-5364(16)30088-7.
 28. Koshak, A. E. and Koshak, P. E. A. (2020) 'Nigella sativa L as a potential phytotherapy for coronavirus disease 2019: A mini review of in silico studies', *Current Therapeutic Research*, 93, p. 100602. doi: 10.1016/j.curtheres.2020.100602.
 29. Kosten, T. R. *et al.* (2018) 'Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: association with pro-inflammatory cytokine levels', *Progress in Neuropsychopharmacology & Biological Psychiatry*, p. #pagerange#. doi: 10.1016/j.pnpbp.2018.04.004.
 30. Kulyar, M. F. *et al.* (2020) 'Phytomedicine Potential influence of Nigella sativa (Black cumin) in reinforcing immune system: A hope to decelerate the COVID-19 pandemic', *Phytomedicine*, (July), p. 153277. doi: 10.1016/j.phymed.2020.153277.
 31. Lee, E. E. *et al.* (2017) 'Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables', *American Journal of Geriatric Psychiatry*, 25(1), pp. 50–61. doi: 10.1016/j.jagp.2016.09.009.
 32. Lee, S. T. H. (2020) 'Inflammation, depression, and anxiety disorder: A population-based study examining the association between Interleukin-6 and the experiencing of depressive and anxiety symptoms', *Psychiatry Research*, 285(January), p. 112809. doi: 10.1016/j.psychres.2020.112809.
 33. Leon, J. De (2020) 'CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis', (July). doi: 10.1002/phar.2434.
 34. Lepiarz, I. *et al.* (2017) 'Inhibition of neuroinflammation by thymoquinone requires activation of Nrf2/ARE signalling', *International Immunopharmacology*, 48(April), pp. 17–29. doi: 10.1016/j.intimp.2017.04.018.
 35. Leza, J. C. *et al.* (2015) 'Neuroscience and Biobehavioral Reviews Inflammation in schizophrenia: A question of balance', *Neuroscience and Biobehavioral Reviews*, 55, pp. 612–626. doi: 10.1016/j.neubiorev.2015.05.014.
 36. Luo, Y. *et al.* (2019) 'Changes in serum TNF- α , IL-18, and IL-6 concentrations in patients with chronic schizophrenia at admission and at discharge', *Comprehensive Psychiatry*, 90, pp. 82–87. doi: 10.1016/j.comppsy.2019.01.003.
 37. LX, L. *et al.* (2004) 'Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia', *Academic Journal of the First Medical College of PLA.*, 24(11), pp. 1251–1254. Available at: <https://europepmc.org/article/med/15567770>.
 38. Mazaheri, Y. *et al.* (2019) 'A Comprehensive Review of the Physicochemical, Quality and Nutritional Properties of Nigella Sativa Oil A Comprehensive Review of the Physicochemical, Quality and Nutritional Properties of Nigella Sativa Oil', *Food Reviews International*, 00(00),

- pp. 1–21. doi: 10.1080/87559129.2018.1563793.
39. Meyer, U. (2013) 'Developmental neuroinflammation and schizophrenia', *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 42, pp. 20–34. doi: 10.1016/j.pnpbp.2011.11.003.
 40. Miller, B. J. *et al.* (2011) 'Meta-analysis of cytokine alterations in schizophrenia: Clinical status and antipsychotic effects', *Biological Psychiatry*, 70(7), pp. 663–671. doi: 10.1016/j.biopsych.2011.04.013.
 41. Miller, B. J. and Goldsmith, D. R. (2017) 'Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions', *Neuropsychopharmacology*, 42(1), pp. 299–317. doi: 10.1038/npp.2016.211.
 42. Mohit, M. *et al.* (2020) 'Complementary Therapies in Medicine Effect of Nigella sativa L . supplementation on inflammatory and oxidative stress indicators : A systematic review and meta-analysis of controlled clinical trials', *Complementary Therapies in Medicine*, 54(July), p. 102535. doi: 10.1016/j.ctim.2020.102535.
 43. Momtazmanesh, S. *et al.* (2019) 'Cytokine Alterations in Schizophrenia: An Updated Review', *Article*, 10, p. 1. doi: 10.3389/fpsy.2019.00892.
 44. Mondelli, V. *et al.* (2015) 'Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis', pp. 1–9. doi: 10.1093/schbul/sbv028.
 45. Monji, A., Kato, T. A. and Kanba, S. (2009) 'Cytokines and schizophrenia : Microglia hypothesis', *Psychiatry and Clinical Neurosciences*, (July). doi: 10.1111/j.1440-1819.2009.01945.x.
 46. Müller, N. *et al.* (2015) 'The role of inflammation in schizophrenia', *Frontiers in Neuroscience*, 9(October). doi: 10.3389/fnins.2015.00372.
 47. Müller, N. (2019) 'COX-2 Inhibitors , Aspirin , and Other Potential Anti-Inflammatory Treatments for Psychiatric Disorders Inflammation and Depression Risk', *Front. Psychiatry*, 10(May), pp. 1–10. doi: 10.3389/fpsy.2019.00375.
 48. Nagi, M. N. and Mansour, M. A. (2000) 'PROTECTIVE EFFECT OF THYMOQUINONE AGAINST DOXORUBICIN – INDUCED CARDIOTOXICITY IN RATS : A POSSIBLE MECHANISM OF PROTECTION', 41(3), pp. 0–6.
 49. Nickavar, B. *et al.* (2003) 'Chemical Composition of the Fixed and Volatile Oils of Nigella sativa L . from Iran', *Z. Naturforsch*, pp. 4–6. Available at: www.znaturforsch.com.
 50. Pvs, M. *et al.* (2016) 'Antioxidant treatments for schizophrenia (Review)', *Cochrane Database of Systematic Reviews*, (2). doi: 10.1002/14651858.CD008919.pub2.www.cochranelibrary.com.
 51. Rashid, A. K. *et al.* (2014) 'Ameliorating effects of thymoquinone in rodent models of schizophrenia', *African Journal of Pharmacy and Pharmacology*, 8(15), pp. 413–421. doi: 10.5897/ajpp2013.3968.
 52. Réus, G. Z. *et al.* (2015) 'The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders', *Neuroscience*, 300(May), pp. 141–154. doi: 10.1016/j.neuroscience.2015.05.018.
 53. Sadock, B. J. V and Sadock, V. A. (2017) *Kaplan & Sadock's Comprehensive textbook of Psychiatry*. 10th edn. Philadelphia: Wolters Kluwer. Available at: <http://library1.nida.ac.th/termpaper6/sd/2554/19755.pdf>.
 54. Saidah, S. *et al.* (2021) 'Levels of Interleukin 6 as a Predictor of Metabolic Syndrome in Schizophrenic Patients Receiving Combination Therapy of Typical and Atypical Antipsychotics', 9, pp. 600–607.
 55. Sayeed, M. S. Bin *et al.* (2013) 'The effect of Nigella sativa Linn . seed on memory , attention and cognition in healthy human volunteers', *Journal of Ethnopharmacology*, pp. 1–8. doi: 10.1016/j.jep.2013.05.004.
 56. Shahdaat, M. *et al.* (2014) 'Journal of Ethnopharmacology Nigella sativa L . seeds modulate mood , anxiety and cognition in healthy adolescent males', *Journal of Ethnopharmacology*, pp. 1–7. doi: 10.1016/j.jep.2013.12.050.
 57. Siagian, D. (2018) *Perbedaan Kadar Serum Interleukin-6 pada Kanker Paru Perokok dan Tidak Perokok. Sumatera Utara*. Available at: <http://repositori.usu.ac.id/handle/123456789/8347>.
 58. Stojanovic, A. *et al.* (2014) 'Increased serum interleukin-6 levels in early stages of psychosis: Associations with at-risk mental states and the severity of psychotic symptoms', *Psychoneuroendocrinology*, 41, pp. 23–32. doi: 10.1016/j.psyneuen.2013.12.005.
 59. Taka, E. *et al.* (2015) 'Anti-inflammatory effects of thymoquinone in activated BV-2

- microglial cells', 286, pp. 5–12. doi: 10.1016/j.jneuroim.2015.06.011.
60. Tanaka, T. *et al.* (2016) 'Regulation of IL-6 in Immunity and Diseases', in Ma, X. (ed.) *Regulation of Cytokine Gene Expression in Immunity and Diseases*,. Springer Science, pp. 79–88. doi: 10.1007/978-94-024-0921-5.
 61. Tanaka, T., Narazaki, M. and Kishimoto, T. (2014) 'IL-6 in Inflammation, Immunity, and Disease', *Cold Spring Harbor Laboratory Press*, 6, pp. 1–16. doi: 10.1101/cshperspect.a016295.
 62. Tavakkoli, A. *et al.* (2017) 'Review on Clinical Trials of Black Seed (*Nigella sativa*) and Its Active Constituent , Thymoquinone', *Journal of Pharmacopuncture*, pp. 179–193. doi: 10.3831/KPI.2017.20.021.
 63. Trovão, N. *et al.* (2019) 'Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia', *Psychiatry Investigation*, 16(3), pp. 177–184. doi: 10.30773/pi.2018.12.19.1.
 64. Uptegrove, R. and Khandaker, G. M. (2020) 'Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia', *Current topics in behavioral neurosciences*. NLM (Medline), pp. 49–66. doi: 10.1007/7854_2018_88.
 65. Woo, T. W. *et al.* (2015) 'Neurobiology of Schizophrenia Onset', *Curr Top Behav Neurosci*, pp. 1–28. doi: 10.1007/7854.
 66. Yazdi, S. *et al.* (2018) 'An Overview on Renoprotective Effects of Thymoquinone', *Kidney Dis*, 9318614139. doi: 10.1159/000486829.
 67. Zaghlol, D. A. A. *et al.* (2012) 'The possible toxic effect of different doses of *Nigella sativa* oil on the histological structure of the liver and renal cortex of adult male albino rats', *Egyptian Journal of Histology*, 35(1), pp. 127–136. doi: 10.1097/01.EHX.0000411396.11951.02.

Lampiran 1

THE POSITIVE AND NEGATIVE SYNDROME (PANSS)

Nama :
Umur :
Tanggal :
Penilai :

Keterangan :

- Nilai 1 : *tidak ada gejala.*
Nilai 2 : *gejala minimal*, gejala masih diragukan keberadaannya/ cenderung tampak normal.
Nilai 3 : *gejala ringan*, gejala jelas, tetapi tidak terlalu berpengaruh pada fungsi keseharian.
Nilai 4 : *gejala sedang*, adanya gejala yang menimbulkan masalah serius sehingga kadang-kadang cukup mengganggu aktivitas keseharian.
Nilai 5 : *gejala agak berat*, manifestasi gejala bermakna yang mempengaruhi fungsi seseorang, tetapi tidak keseluruhan hidup, dan masih dapat diatasi.
Nilai 6 : *gejala berat*, psikopatologi yang berat dan frekuensinya sering, sangat mengganggu kehidupan seseorang dan selalu membutuhkan pengawasan langsung.
Nilai 7 : *gejala sangat berat*, merujuk pada psikopatologi dengan level serius, sangat mempengaruhi hampir seluruh fungsi kehidupan sehingga membutuhkan pengawasan ketat.

Gejala Positif (P)

Gejala	1	2	3	4	5	6	7
P1. Waham							
P2. Kekacauan proses pikir							
P3. Halusinasi							
P4. Gaduh gelisah							
P5. Waham kebesaran							
P6. Kecurigaan atau kejaran							
P7. Permusuhan							

Gejala Negatif (N)

Gejala	1	2	3	4	5	6	7
N1. Afek tumpul							
N2. Penarikan emosi							
N3. Kemiskinan <i>rapport</i>							
N4. Penarikan diri							
N5. Pemikiran abstrak							
N6. Spontanitas dan arus percakapan							
N7. Pemikiran stereotipik							

Skala Psikopatologi Umum (G)

Gejala	1	2	3	4	5	6	7
G1. Kekhawatiran somatik							
G2. Ansietas							
G3. Rasa bersalah							
G4. Ketegangan							
G5. Manerisme dan sikap tubuh							
G6. Depresi							
G7. Retardasi motorik							
G8. Ketidakkoperatipan							

G9. Isi pikiran yang tidak biasa							
G10. Disorientasi							
G11. Perhatian buruk							
G12. Kurangnya daya nilai dan tilikan							
G13. Gangguan dorongan kehendak							
G14. Pengendalian impuls yg buruk							
G15. Preokupasi							
G16. Penghindaran sosial secara aktif							

Lampiran 2 Izin Penelitian



PEMERINTAH PROVINSI SULAWESI SELATAN
DINAS PENANAMAN MODAL DAN PELAYANAN TERPADU SATU PINTU
BIDANG PENYELENGGARAAN PELAYANAN PERIZINAN

Nomor : 12163/B.01/PTMP/2021
Lampiran :
Perihal : Izin Penelitian

Kepada Yth.
Direktur Rumah Sakit Khusus Daerah Prov. Sulsel

di
Tempat

Berlasailakan surat Ketua Prog. Studi Dep. Ilmu Kedokteran Jiwa Fak. Kedokteran Univ. Hasanudin Makassar Nomor : 4884/UN4.6/MT.01.04/2021 tanggal 06 Maret 2021 perihal tersebut diatas, mahasiswa/peneliti dibawah ini

Nama : NRI PURWATININGSIH
Nomor Pokok : C005171005
Program Studi : Ilmu Kedokteran Jiwa
Pekerjaan/ Lembaga : Mahasiswa(S2)
Alamat : Jl. P. Kemerdekaan Km. 10, Makassar

Bermaksud untuk melakukan penelitian di daerah/kantor saudara dalam rangka penyusunan Tesis, dengan judul

" EFIKASI JINTAN HITAM (NIGELLA SATIVA) TERHADAP PERBAIKAN INTERLEUKIN-6 DAN GEJALA KLINIS PASIEN SKIZOFRENIA "

Yang akan dilaksanakan dari : Tgl. 20 Maret s/d 30 Mei 2021

Selubungan dengan hal tersebut diatas, pada prinsipnya kami *menyetujui* kegiatan dimaksud dengan ketentuan yang tertera di belakang surat izin penelitian.

Dokumen ini ditandatangani secara elektronik dan Surat ini dapat dibuktikan keasliannya dengan menggunakan *barcode*.

Demikian surat izin penelitian ini diberikan agar dipergunakan sebagaimana mestinya.

Diterbitkan di Makassar
Pada tanggal : 15 Maret 2021

A.n. GUBERNUR SULAWESI SELATAN
KEPALA DINAS PENANAMAN MODAL DAN PELAYANAN TERPADU
SATU PINTU PROVINSI SULAWESI SELATAN
Selaku Administrator Pelayanan Perizinan Terpadu

Dr. JAYADI NAS, S.Sos., M.Si
Pangkat : Pembina Tk I
Nip : 107105011008031004

Terselamatkan Yth
1. Ketua Prog. Studi Dep. Ilmu Kedokteran Jiwa Fak. Kedokteran Univ. Hasanudin Makassar di Makassar,
2. Peringgal

SMP/PTSP 15 03 2021



Jl. Bougainville No.8 Telp. (0411) 441077 Fax (0411) 448036
Website : <http://aimap.sulawesiprov.go.id> Email : ptsp@sulawesiprov.go.id
Makassar 90231



Lampiran 3 Rekomendasi Persetujuan Etik



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari., MMed.PhD, SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 248/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 15 April 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21030162	No Sponsor Protokol	
Peneliti Utama	dr. Sri Purwatiningsih	Sponsor	
Judul Peneliti	EFIKASI JINTAN HITAM (NigellaeSativa) TERHADAP PERBAIKAN INTERLEUKIN-6 DAN GEJALA KLINIS PASIEN SKIZOFRENIA		
No Versi Protokol	2	Tanggal Versi	9 April 2021
No Versi PSP	2	Tanggal Versi	9 April 2021
Tempat Penelitian	RS Universitas Hasanuddin dan Jejaring di Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input checked="" type="checkbox"/> Fullboard Tanggal 7 April 2021	Masa Berlaku 15 April 2021 sampai 15 April 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 5

1. Pengambilan sampel RSKD Dadi Provinsi Sulawesi Selatan



2. Alat dan bahan pemeriksaan Elisa Interleukine 6



3. Pengerjaan sampel Laboratorium RSP Universitas Hasanuddin

